Previous Close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expire Date | 2024-11-15 |
Day's Range | 0.2000 - 0.2000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (“CGM”) solution towards market launch. Since acquiring the CGM technology earlier in the year, Trinity Biotech has been working on further innovations and improvements to the original device. The Company
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. Management plans to host meetings with key stakeholders and potential partners as it works t
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”) microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company’s stakeholders with key insights into the Company’s vision for the development of the next generation of its recently acqu